SCHEMBL15210909

SCHEMBL15210909

NCC1CCN(CC(=O)O)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLG P00747 1/20 0.47
PLAT P00750 1/20 0.47
LMNA P02545 1/20 0.47
HSD17B10 Q99714 1/20 0.45
NCF1 P14598 1/20 0.45
CYP2D6 P10635 1/20 0.39
CXCR4 P61073 1/20 0.39
ITGB3 P05106 2/20 0.38
ITGA2B P08514 2/20 0.38
CHRM2 P08172 1/20 0.38
CHRM1 P11229 1/20 0.38
CHRM3 P20309 1/20 0.38
ALOX15 P16050 1/20 0.38
GRIN2D O15399 1/20 0.35
GRIN3B O60391 1/20 0.35
ADRA1D P25100 1/20 0.35
ADRA1A P35348 1/20 0.35
ADRA1B P35368 1/20 0.35
GRIN1 Q05586 1/20 0.35
GRIN2A Q12879 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23523301 0.83 KDM4E (0.50) PLGPLATLMNANCF1CYP2D6
Hydrochloric Acid SCHEMBL23522810 0.82 KDM4E (0.48) PLGPLATLMNANCF1CYP2D6
SCHEMBL18173237 0.81 HSD17B10 (0.47) HSD17B10ITGB3ITGA2BALOX15GRIN2D
SCHEMBL21472144 0.80 GLA (0.48) PLGPLATLMNANCF1CYP2D6
SCHEMBL14609561 0.79 HSD17B10 (0.45) HSD17B10ITGB3ITGA2BGRIN2DGRIN3B
SCHEMBL6889226 0.79 HSD17B10 (0.45) HSD17B10
SCHEMBL19325901 0.79 HSD17B10 (0.41) HSD17B10ITGB3ITGA2BCHRM3ALOX15
SCHEMBL1644494 0.78 HSD17B10 (0.48) HSD17B10ITGB3ITGA2BALOX15
SCHEMBL188132 0.78 HSD17B10 (0.48) HSD17B10ITGB3ITGA2BALOX15
SCHEMBL7359289 0.78 HSD17B10 (0.44) HSD17B10ITGB3ITGA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2688568-B1 CYCLOPROPYLAMINES AS LSD1 INHIBITORS GLAXOSMITHKLINE IP NO 2 LTD (GB) 2019-06-19 EP disclosed
US-10160746-B2 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 2018-12-25 US disclosed
US-20170174657-A1 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R. A.F. S.P.A. (IT) 2017-06-22 US disclosed
US-20170157121-A1 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 2017-06-08 US disclosed
EP-2817302-B1 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS ACRAF (IT) 2015-12-30 EP disclosed
EP-2817301-B1 USE OF 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS ACRAF (IT) 2015-12-23 EP disclosed
EP-2817302-A1 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. (IT) 2014-12-31 EP disclosed
EP-2817301-A1 USE OF 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO - A.C.R.A.F. - S.p.A. (IT) 2014-12-31 EP disclosed
WO-2013124158-A1 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 2013-08-29 WO disclosed
WO-2013124169-A1 USE OF 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 2013-08-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10160746-B2 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors GSK3B, GSK3A, PYGB PLG 3557/4885PLAT 3962/4885LMNA 2344/4885
US-20170157121-A1 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS GSK3B, GSK3A, PYGB PLG 3557/4885PLAT 3962/4885LMNA 2344/4885
US-20170174657-A1 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS GSK3B, GSK3A, PYGB PLG 3557/4885PLAT 3962/4885LMNA 2344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.